Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism

Laron, Zvi; Anin, S.; Klipper-Aurbach, Yaffa; Klinger, B.

doi:10.1016/0140-6736(92)91594-x

Cited by 203 publications

(100 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A modest, but significant dose dependency was observed during that first year of therapy. These findings differ somewhat from an earlier report from Ecuador, which showed no difference in 1-and 2-year growth responses to 80 vs 120 mg/kg twice a day (9). Since the Ecuador study was confined to patients homozygous for a severe mutation of GHR, characterized by markedly reduced serum concentrations of not only IGF-I but also IGF-binding protein-3 (IGFBP-3) and ALS, it is not entirely clear whether the lack of differential response to IGF-I dosage reflects limitations induced by the low serum levels of IGFBPs.…”

Section: Igf-i Therapycontrasting

confidence: 57%

“…Whether expressed as mean height velocity, dheight velocity over baseline, or dheight SDS, IGF-I Rx fails to parallel results with GH therapy of GHD (9). A variety of explanations have been proposed: 1) failure to identify optimal IGF-I dosage; 2) failure of IGF-I treatment (unlike GH treatment of GHD) to normalize the typically low serum concentrations of IGFBP-3 and ALS, resulting in rapid clearance of administered IGF-I; 3) failure of injected IGF-I to fully reach the epiphyseal growth plate, compounded by the potential ability of GH to stimulate local production of IGF-I in epiphyseal chondrocytes; and 4) possible IGF-independent actions of GH on skeletal growth.…”

Section: Igf-i Therapymentioning

confidence: 99%

See 1 more Smart Citation

IGF-I therapy in growth disorders

Rosenfeld¹

2007

eur j endocrinol

View full text Add to dashboard Cite

show abstract

Section: Igf-i Therapycontrasting

confidence: 57%

Section: Igf-i Therapymentioning

confidence: 99%

IGF-I therapy in growth disorders

Rosenfeld¹

2007

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…28 A growing body of data suggests that the role of the insulin growth factor family in the regulation of the early stages of hemopoiesis might be over-stated. Accordingly, mice with deletional mutations of genes encoding IGF-I, IGF-2, IGF-R and IRS-1, [39][40][41][42][43] Laron dwarf patients with drastically reduced IGF-I levels 44 or acromegalic patients with elevated IGF-I levels, all show normal erythropoiesis. 45 Moreover, the individuals with an inherited absence of INS-R, 46,47 and IGF-I 48 were found to also be hematologically normal.…”

Section: Discussionmentioning

confidence: 99%

The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors

et al. 1998

View full text Add to dashboard Cite

The role of insulin (INS), and insulin-like growth factor-I (IGF-I Both INS and IGF-I activated signal transduction in maturing human erythropoietic cells as determined by phosphorylation of the insulin receptor substrate-2 (IRS-2) protein. We also found by RT-PCR that mRNA coding for INS-R is expressed in FACS sorted CD34؉ , c-kit-R ؉ marrow cells, and in cells isolated from BFU-E and CFU-GM colonies. Expression of INS-R protein on these cells was subsequently confirmed by cytofluorometry. In contrast, the receptor for insulin-like growth factor-I (IGF-IR) was not detected on CD34؉ cells, and was first easily detectable on more differentiated cells derived from day 6 BFU-E and CFU-GM colonies. We conclude that INS and IGF-I may be survival factors for human CD34 ؉ cells, but are not required during early erythropoiesis. In contrast, both growth factors may play some role at the final stages of erythroid maturation.

show abstract

“…Recombinant human IGF-I has been used to exert a growth-promoting effect in patients with Laron-type dwarfism [13]. It has also been used as a glucose-lowering agent in patients with extreme insulin resistance syndromes including Rabson-Mendenhall syndrome [7], type A insulin resistance [6,8], congenital generalized lipodystrophy and leprechaunism [6].…”

Section: Resultsmentioning

confidence: 99%

A Case of Non-Insulin Dependent Diabetes Mellitus with Antiinsulin Antibody: Effect of Subcutaneous Injection of Human Recombinant Insulin-like Growth Factor-I.

et al. 1995

View full text Add to dashboard Cite

Abstract. We saw a 57-yr-old female non-insulin dependent diabetes mellitus (NIDDM) patient with antiinsulin antibody, in whom insulin-like growth factor-I (IGF-I) was shown to be effective as a blood glucose-lowering agent. Due to the presence of the antibody, the patient suffered from postprandial hyperglycemia and frequent hypoglycemia, which were uncontrollable even by multiple insulin injection therapy. In contrast to insulin injection (0.24 IU/kg body wt) which showed a delayed glucoselowering effect, subcutaneous injection of recombinant human IGF-I (0.05-0.1 mg/kg body wt) caused a quick fall in plasma glucose levels. Prolongation of the glucose-lowering effect of "rapid-acting" insulin frequently caused subsequent hypoglycemia in this patient, but the effect of IGF-I seemed to have disappeared within the first three hours.Key words: IGF-I, Antiinsulin antibody (Endocrine Journal 42:101-105,1995) ANTIINSULIN antibody, which can frequently be identified in patients receiving long-term insulin injection therapy, often causes both a delayed onset and prolongation of insulin effects. This is often associated with unexpected hypoglycemia, and thus the presence of antiinsulin antibody is frequently found in "brittle-type" diabetes.We recently had a female patient with non-insulin dependent diabetes mellitus (NIDDM) who suffered from frequent hypo-and hyperglycemia due to the presence of antiinsulin antibody. As a step to exploring the potential of insulin-like growth factor-I (IGF-I) use for diabetic patients, the effect of IGF-I as a glucose-lowering agent in this NIDDM case was examined. A 57-yr-old Japanese woman with a 26-year history of diabetes mellitus. She started using porcine insulin 13 years ago and then human insulin 6 years ago, when multiple insulin injection therapy was introduced. The daily profile of the plasma glucose level revealed typical postprandial hyperglycemia that was uncontrollable even by preprandial subcutaneous injection of "rapid-acting" insulin; the plasma glucose concentration, which had been 90 mg/dl before breakfast, rose up to 292 mg/dl two hours after it (2 h 15 min after injection of 0.33 IU/ kg body wt insulin). Thus the "rapid-acting" insulin showed a delayed and yet prolonged glucose-lowering effect in this patient. When the present trial was performed, the patient took a "rapid -acting" insulin injection twice daily (0.33 IU/kg body wt in the morning and 0.16 IU/kg body wt in the evening) and her fasting serum C-

show abstract

Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism

Cited by 203 publications

References 17 publications

IGF-I therapy in growth disorders

IGF-I therapy in growth disorders

The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors

A Case of Non-Insulin Dependent Diabetes Mellitus with Antiinsulin Antibody: Effect of Subcutaneous Injection of Human Recombinant Insulin-like Growth Factor-I.

Contact Info

Product

Resources

About